OccuRx
Primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis.
Launch date
Employees
Market cap
-
Enterprise valuation
$38—56m (Dealroom.co estimates Sep 2022.)
Company register number 164284440
Melbourne Victoria (HQ)
Authorizing premium user...